[go: up one dir, main page]

WO2002070004A3 - Papillomavirus vaccines - Google Patents

Papillomavirus vaccines Download PDF

Info

Publication number
WO2002070004A3
WO2002070004A3 PCT/GB2002/000975 GB0200975W WO02070004A3 WO 2002070004 A3 WO2002070004 A3 WO 2002070004A3 GB 0200975 W GB0200975 W GB 0200975W WO 02070004 A3 WO02070004 A3 WO 02070004A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogens
immune response
papillomavirus
vaccines
response against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/000975
Other languages
French (fr)
Other versions
WO2002070004A2 (en
Inventor
Julian Kingdon Hickling
Terry O'neill
Rienk Offringa
Der Burg Sjoerd Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenova Research Ltd
Leids Universitair Medisch Centrum LUMC
Original Assignee
Xenova Research Ltd
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Research Ltd, Leids Universitair Medisch Centrum LUMC filed Critical Xenova Research Ltd
Priority to AU2002236065A priority Critical patent/AU2002236065A1/en
Priority to BR0207899A priority patent/BR0207899A/en
Priority to JP2002569176A priority patent/JP2004522789A/en
Priority to EP02702541A priority patent/EP1399182A2/en
Publication of WO2002070004A2 publication Critical patent/WO2002070004A2/en
Anticipated expiration legal-status Critical
Publication of WO2002070004A3 publication Critical patent/WO2002070004A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to immunogens and vaccines and to their preparation and use. In particular, the invention extends to combination immunogens comprising a primer and a booster immunogen directed against papillomavirus protein antigens, and their use to stimulate an immune response against papillomaviruses, such as a prophylactic or therapeutic immune response against human papillomavirus (HPV) infection.
PCT/GB2002/000975 2001-03-07 2002-03-07 Papillomavirus vaccines Ceased WO2002070004A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002236065A AU2002236065A1 (en) 2001-03-07 2002-03-07 Papillomavirus vaccines
BR0207899A BR0207899A (en) 2001-03-07 2002-03-07 Combination immunogen for sequential administration of components to elicit an immune response against papillomavirus, a pharmaceutical product, use of a pharmaceutical product, and method for eliciting an immune response against papillomavirus in a patient
JP2002569176A JP2004522789A (en) 2001-03-07 2002-03-07 Papillomavirus vaccine
EP02702541A EP1399182A2 (en) 2001-03-07 2002-03-07 Papillomavirus vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0105606A GB0105606D0 (en) 2001-03-07 2001-03-07 Immunogens and vaccines and their preparation and use
GB0105606.8 2001-03-07

Publications (2)

Publication Number Publication Date
WO2002070004A2 WO2002070004A2 (en) 2002-09-12
WO2002070004A3 true WO2002070004A3 (en) 2003-12-31

Family

ID=9910150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/000975 Ceased WO2002070004A2 (en) 2001-03-07 2002-03-07 Papillomavirus vaccines

Country Status (6)

Country Link
EP (1) EP1399182A2 (en)
JP (1) JP2004522789A (en)
AU (1) AU2002236065A1 (en)
BR (1) BR0207899A (en)
GB (1) GB0105606D0 (en)
WO (1) WO2002070004A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013326B1 (en) * 2005-04-26 2010-04-30 Глаксосмитклайн Байолоджикалс С.А. Vaccine
EP2289516B1 (en) * 2005-04-27 2014-01-08 Leiden University Medical Center Methods and means for the treatment of HPV induced intraepithelial neoplasias
EP2199301A1 (en) * 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof
BR112018075420A2 (en) 2016-06-07 2019-03-12 Deutsches Krebsforschungszentrum enhancement of petid l2 immunogenicity
CA3091969A1 (en) * 2018-02-22 2019-08-29 Turnstone Limited Partnership Oncolytic viruses as adjuvants
CN112439059B (en) * 2019-09-02 2022-02-08 怡道生物科技(苏州)有限公司 Recombinant human papilloma virus vaccine composition and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016636A1 (en) * 1991-03-14 1992-10-01 Cantab Pharmaceuticals Research Limited Recombinant virus vectors encoding human papillomavirus proteins
WO1996026277A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
WO2000011140A1 (en) * 1998-08-20 2000-03-02 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
WO2001014416A2 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic papillomavirus genes optimized for expression in human cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016636A1 (en) * 1991-03-14 1992-10-01 Cantab Pharmaceuticals Research Limited Recombinant virus vectors encoding human papillomavirus proteins
WO1996026277A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
WO2000011140A1 (en) * 1998-08-20 2000-03-02 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
WO2001014416A2 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic papillomavirus genes optimized for expression in human cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN C-H ET AL: "Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 18, no. 19, April 2000 (2000-04-01), pages 2015 - 2022, XP004202497, ISSN: 0264-410X *
MURAKAMI MASARU ET AL: "Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells.", CANCER RESEARCH, vol. 59, no. 6, 15 March 1999 (1999-03-15), pages 1184 - 1187, XP002238464, ISSN: 0008-5472 *
RAMSHAW I A ET AL: "The prime - boost strategy: Exciting prospects for improved vaccination", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 4, April 2000 (2000-04-01), pages 163 - 165, XP002179214, ISSN: 0167-5699 *
VAN DER BURG S H ET AL: "Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 27, 14 June 2001 (2001-06-14), pages 3652 - 3660, XP004241783, ISSN: 0264-410X *

Also Published As

Publication number Publication date
WO2002070004A2 (en) 2002-09-12
BR0207899A (en) 2004-10-19
GB0105606D0 (en) 2001-04-25
JP2004522789A (en) 2004-07-29
EP1399182A2 (en) 2004-03-24
AU2002236065A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
WO1999033868A3 (en) Human papillomavirus vaccine
WO2004075829A3 (en) Adjuvanted influenza vaccine
WO1999010375A3 (en) Vaccine against hpv
MXPA02005639A (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions.
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
WO2003028632A3 (en) Development of a preventive vaccine for filovirus infection in primates
WO2003028760A3 (en) Vaccine
WO2001034801A3 (en) Recombinant gelatin in vaccines
WO2004014418A3 (en) Neisserial vaccine compositions comprising a combination of antigens
PT1409692E (en) Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine
AUPN015794A0 (en) Variants of human papilloma virus antigens
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
WO2001054719A3 (en) Vaccine for the prophylactic or therapeutic immunization against hiv
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
WO2002013857A3 (en) A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
WO2002034205A3 (en) Using heat shock proteins to increase immune response
WO2003038047A3 (en) Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
WO2000062801A3 (en) Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv)
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
WO2002087494A3 (en) Novel vaccine
WO2003063899A3 (en) Vaccine adjuvant based on a cd4 0 ligand
WO2003066094A3 (en) Hepatitis b vaccines
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
WO2003059385A3 (en) Hiv vaccine and method of use
WO2004037175A3 (en) Compositions and methods for treating human papillomavirus-mediated disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002702541

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002569176

Country of ref document: JP

Ref document number: PA/A/2003/007982

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 028074173

Country of ref document: CN

Ref document number: 1249/KOLNP/2003

Country of ref document: IN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002702541

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002702541

Country of ref document: EP